Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress

Yao Zhang, Jinzhi Lai, Zhanwen Du, Jinnan Gao, Shuming Yang, Shashank Gorityala, Xiahui Xiong, Ou Deng, Zhefu Ma, Chunhong Yan, Gonzalo Susana, Yan Xu, Junran Zhang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Radiotherapy (RT) remains a standard therapeutic modality for breast cancer patients. However, intrinsic or acquired resistance limits the efficacy of RT. Here, we demonstrate that CHK1 inhibitor AZD7762 alone significantly inhibited the growth of radioresistant breast cancer cells (RBCC). Given the critical role of ATR/CHK1 signaling in suppressing oncogene-induced replication stress (RS), we hypothesize that CHK1 inhibition leads to the specific killing for RBCC due to its abrogation in the suppression of RS induced by oncogenes. In agreement, the expression of oncogenes c-Myc/CDC25A/c-Src/H-ras/E2F1 and DNA damage response (DDR) proteins ATR/ CHK1/BRCA1/CtIP were elevated in RBCC. AZD7762 exposure led to significantly higher levels of RS in RBCC, compared to the parental cells. The mechanisms by which CHK1 inhibition led to specific increase of RS in RBCC were related to the interruptions in the replication fork dynamics and the homologous recombination (HR). In summary, RBCC activate oncogenic pathways and thus depend upon mechanisms controlled by CHK1 signaling to maintain RS under control for survival. Our study provided the first example where upregulating RS by CHK1 inhibitor contributes to the specific killing of RBCC, and highlight the importance of the CHK1 as a potential target for treatment of radioresistant cancer cells.

Original languageEnglish (US)
Pages (from-to)34688-34702
Number of pages15
JournalOncotarget
Volume7
Issue number23
DOIs
StatePublished - Jun 7 2016

Fingerprint

Breast Neoplasms
Oncogenes
Radiotherapy
myc Genes
Homologous Recombination
DNA Damage
Survival
Therapeutics
Growth
Neoplasms
Proteins

Keywords

  • CHK1 inhibitor
  • Double strand break repair
  • Homologous recombination
  • Radioresistance
  • Replication stress

ASJC Scopus subject areas

  • Oncology

Cite this

Zhang, Y., Lai, J., Du, Z., Gao, J., Yang, S., Gorityala, S., ... Zhang, J. (2016). Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress. Oncotarget, 7(23), 34688-34702. https://doi.org/10.18632/oncotarget.9156

Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress. / Zhang, Yao; Lai, Jinzhi; Du, Zhanwen; Gao, Jinnan; Yang, Shuming; Gorityala, Shashank; Xiong, Xiahui; Deng, Ou; Ma, Zhefu; Yan, Chunhong; Susana, Gonzalo; Xu, Yan; Zhang, Junran.

In: Oncotarget, Vol. 7, No. 23, 07.06.2016, p. 34688-34702.

Research output: Contribution to journalArticle

Zhang, Y, Lai, J, Du, Z, Gao, J, Yang, S, Gorityala, S, Xiong, X, Deng, O, Ma, Z, Yan, C, Susana, G, Xu, Y & Zhang, J 2016, 'Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress', Oncotarget, vol. 7, no. 23, pp. 34688-34702. https://doi.org/10.18632/oncotarget.9156
Zhang, Yao ; Lai, Jinzhi ; Du, Zhanwen ; Gao, Jinnan ; Yang, Shuming ; Gorityala, Shashank ; Xiong, Xiahui ; Deng, Ou ; Ma, Zhefu ; Yan, Chunhong ; Susana, Gonzalo ; Xu, Yan ; Zhang, Junran. / Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress. In: Oncotarget. 2016 ; Vol. 7, No. 23. pp. 34688-34702.
@article{9db511374f424df9adaeab9f8a1784e0,
title = "Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress",
abstract = "Radiotherapy (RT) remains a standard therapeutic modality for breast cancer patients. However, intrinsic or acquired resistance limits the efficacy of RT. Here, we demonstrate that CHK1 inhibitor AZD7762 alone significantly inhibited the growth of radioresistant breast cancer cells (RBCC). Given the critical role of ATR/CHK1 signaling in suppressing oncogene-induced replication stress (RS), we hypothesize that CHK1 inhibition leads to the specific killing for RBCC due to its abrogation in the suppression of RS induced by oncogenes. In agreement, the expression of oncogenes c-Myc/CDC25A/c-Src/H-ras/E2F1 and DNA damage response (DDR) proteins ATR/ CHK1/BRCA1/CtIP were elevated in RBCC. AZD7762 exposure led to significantly higher levels of RS in RBCC, compared to the parental cells. The mechanisms by which CHK1 inhibition led to specific increase of RS in RBCC were related to the interruptions in the replication fork dynamics and the homologous recombination (HR). In summary, RBCC activate oncogenic pathways and thus depend upon mechanisms controlled by CHK1 signaling to maintain RS under control for survival. Our study provided the first example where upregulating RS by CHK1 inhibitor contributes to the specific killing of RBCC, and highlight the importance of the CHK1 as a potential target for treatment of radioresistant cancer cells.",
keywords = "CHK1 inhibitor, Double strand break repair, Homologous recombination, Radioresistance, Replication stress",
author = "Yao Zhang and Jinzhi Lai and Zhanwen Du and Jinnan Gao and Shuming Yang and Shashank Gorityala and Xiahui Xiong and Ou Deng and Zhefu Ma and Chunhong Yan and Gonzalo Susana and Yan Xu and Junran Zhang",
year = "2016",
month = "6",
day = "7",
doi = "10.18632/oncotarget.9156",
language = "English (US)",
volume = "7",
pages = "34688--34702",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress

AU - Zhang, Yao

AU - Lai, Jinzhi

AU - Du, Zhanwen

AU - Gao, Jinnan

AU - Yang, Shuming

AU - Gorityala, Shashank

AU - Xiong, Xiahui

AU - Deng, Ou

AU - Ma, Zhefu

AU - Yan, Chunhong

AU - Susana, Gonzalo

AU - Xu, Yan

AU - Zhang, Junran

PY - 2016/6/7

Y1 - 2016/6/7

N2 - Radiotherapy (RT) remains a standard therapeutic modality for breast cancer patients. However, intrinsic or acquired resistance limits the efficacy of RT. Here, we demonstrate that CHK1 inhibitor AZD7762 alone significantly inhibited the growth of radioresistant breast cancer cells (RBCC). Given the critical role of ATR/CHK1 signaling in suppressing oncogene-induced replication stress (RS), we hypothesize that CHK1 inhibition leads to the specific killing for RBCC due to its abrogation in the suppression of RS induced by oncogenes. In agreement, the expression of oncogenes c-Myc/CDC25A/c-Src/H-ras/E2F1 and DNA damage response (DDR) proteins ATR/ CHK1/BRCA1/CtIP were elevated in RBCC. AZD7762 exposure led to significantly higher levels of RS in RBCC, compared to the parental cells. The mechanisms by which CHK1 inhibition led to specific increase of RS in RBCC were related to the interruptions in the replication fork dynamics and the homologous recombination (HR). In summary, RBCC activate oncogenic pathways and thus depend upon mechanisms controlled by CHK1 signaling to maintain RS under control for survival. Our study provided the first example where upregulating RS by CHK1 inhibitor contributes to the specific killing of RBCC, and highlight the importance of the CHK1 as a potential target for treatment of radioresistant cancer cells.

AB - Radiotherapy (RT) remains a standard therapeutic modality for breast cancer patients. However, intrinsic or acquired resistance limits the efficacy of RT. Here, we demonstrate that CHK1 inhibitor AZD7762 alone significantly inhibited the growth of radioresistant breast cancer cells (RBCC). Given the critical role of ATR/CHK1 signaling in suppressing oncogene-induced replication stress (RS), we hypothesize that CHK1 inhibition leads to the specific killing for RBCC due to its abrogation in the suppression of RS induced by oncogenes. In agreement, the expression of oncogenes c-Myc/CDC25A/c-Src/H-ras/E2F1 and DNA damage response (DDR) proteins ATR/ CHK1/BRCA1/CtIP were elevated in RBCC. AZD7762 exposure led to significantly higher levels of RS in RBCC, compared to the parental cells. The mechanisms by which CHK1 inhibition led to specific increase of RS in RBCC were related to the interruptions in the replication fork dynamics and the homologous recombination (HR). In summary, RBCC activate oncogenic pathways and thus depend upon mechanisms controlled by CHK1 signaling to maintain RS under control for survival. Our study provided the first example where upregulating RS by CHK1 inhibitor contributes to the specific killing of RBCC, and highlight the importance of the CHK1 as a potential target for treatment of radioresistant cancer cells.

KW - CHK1 inhibitor

KW - Double strand break repair

KW - Homologous recombination

KW - Radioresistance

KW - Replication stress

UR - http://www.scopus.com/inward/record.url?scp=84973596273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973596273&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9156

DO - 10.18632/oncotarget.9156

M3 - Article

C2 - 27167194

AN - SCOPUS:84973596273

VL - 7

SP - 34688

EP - 34702

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -